Boehringer Ingelheim Pursuing Health Care Innovation ? New Collaboration with Healthrageous, Inc on a Digital Diabetes Self-management Program
Ingelheim, 10 July, 2012 – In future patients with certain diseases, especially chronic ones, should be treated in a more holistic approach beyond drug treatment only. Thus Boehringer Ingelheim is concentrating on new business models and healthcare innovation and just signed a contract with the US company Healthrageous, Inc., a digital health management company.
Both companies will evaluate in a pilot study a lifestyle behavior modification program to improve the health status of people with diabetes Type 2. Study participants will experience a digital technology intervention combining digital coaching and a wireless glucose meter transmitting data to clinical monitors.
The Internet-based tool will allow an evaluation of the
intervention on changes in lifestyle behaviors, glucose control,
additional medical parameters and medication adherence.
Bert Tjeenk-Willink, Member of the Board of Managing Directors of Boehringer Ingelheim
"Boehringer Ingelheim is known for innovation in research and development and for bringing high quality medications quickly to the market. But we are also committed to a "beyond pill" approach in health care. We have to pursue a new approach to see the patient with all his or her aspirations but also limitations. We need to find suitable answers that will benefit not only the patients and their family but also the whole society in so far that healthier patients lead a more satisfactory life and can contribute to society for longer." said Bert Tjeenk-Willink, Member of the Board of Managing Directors of Boehringer Ingelheim. "This first initiative offering a comprehensive digital platform for Type 2 diabetes will help us to better understand what motivates individuals to become and remain engaged in self-managing their health. We are delighted to be working with Healthrageous here. Boehringer Ingelheim will engage in many more initiatives of that kind."
An estimated 366 million people worldwide have type 1 and type 2 diabetes. Type 2 diabetes is the most common type, accounting for an estimated 90 to 95% of all diabetes cases. The number is expected to grow considerably in the next years due to unhealthy lifestyles. Conclusions from findings in Behavioural Science show that in most chronic medical conditions and diseases such as diabetes, Chronic Obstructive Pulmonary Disease (COPD) or high blood pressure interventions with respect to drug adherence, lifestyle changes in nutrition, physical exercises, stress reduction and can bring about measureable improvements. The most important aspect, however, is that the patient sticks to a chosen regimen and properly manages his/her lifestyle change.
The goal of the new diabetes program is to leverage technology
in a way that makes the personalized journey of self-managing
diabetes easier and more effective. During the collaboration, in a
first phase 200 adults in the U.S. diagnosed with Type 2 diabetes
for at least six months will have access to Healthrageous’
digital diabetes self-management program. The web and smartphone
delivered program will include a personalized action plan with
health behavior improvement goals, biometric feedback to
demonstrate goal achievement and milestones, digital coach
interaction, recognition and incentives for progress, supply and
strip refill ordering, medication reminders, and social networking
support. If the results show the expected benefits, the program
will be expanded to encompass up to one thousand patients in
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.
In 2011, Boehringer Ingelheim achieved net sales of about 13.2
billion euro. R&D expenditure in the business area Prescription
Medicines corresponds to 23.5% of its net sales.
Head of Global Media & PR
Judith von Gordon
Binger Strasse 173
55216 Ingelheim am Rhein
Phone +49/6132/77 35 82
Fax +49/6132/77 66 01
Posted: July 2012